This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Sabbe, R. Articles by Mosier, D. E. Search for Related Content PubMed PubMed Citation Articles by Sabbe, R. Articles by Mosier, D. E.

Journal of Virology, January 2001, p. 661-671, Vol. 75, No. 2
0022-538X/01/$04.00+0   DOI: 10.1128/JVI.75.2.661-671.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.

Donor- and Ligand-Dependent Differences in C-C Chemokine Receptor 5 Reexpression

Rebecca Sabbe,¹ Gastón R. Picchio,¹ Cristina Pastore,¹ Olivier Chaloin,² Oliver Hartley,² Robin Offord,² and Donald E. Mosier^1,*

Department of Immunology, The Scripps Research Institute, La Jolla, California 92037,¹ and Département de Biochimie Médicale, Centre Medical Universitaire, Geneva 1228, Switzerland²

Received 16 August 2000/Accepted 25 October 2000

N-terminal modifications of the chemokine RANTES bind to C-C chemokine receptor 5 (CCR5) and block human immunodeficiency virus type 1 (HIV-1) infection with greater efficacy than native RANTES. Modified RANTES compounds induce rapid CCR5 internalization and much slower receptor reexpression than native RANTES, suggesting that receptor sequestration is one mode of anti-HIV activity. The rates of CCR5 internalization and reexpression were compared using the potent n-nonanoyl (NNY)-RANTES derivative and CD4⁺ T cells derived from donors with different CCR5 gene polymorphisms. NNY-RANTES caused even more rapid receptor internalization and slower reexpression than aminooxypentane (AOP)-RANTES. Polymorphisms in the promoter and coding regions of CCR5 significantly affected the receptor reexpression rate after exposure of cells to NNY-RANTES. These observations may be relevant for understanding the protective effects of different CCR5 genotypes against HIV-1 disease progression.

---

^* Corresponding author. Mailing address: Department of Immunology, IMM7, The Scripps Research Institute, 10550 N. Torrey Pines Rd., La Jolla, CA 92037. Phone: (858) 784-9121. Fax: (858) 784-9190. E-mail: dmosier{at}scripps.edu.

Publication 13345-IMM from The Scripps Research Institute.

---

Journal of Virology, January 2001, p. 661-671, Vol. 75, No. 2
0022-538X/01/$04.00+0   DOI: 10.1128/JVI.75.2.661-671.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.

This article has been cited by other articles:

• Gupta, S., Fuchs, B., Schulz-Maronde, S., Heitland, A., Escher, S. E., Mack, M., Tillmann, H.-C., Braun, A., Forssmann, W.-G., Elsner, J., Forssmann, U. (2008). Intravascular inactivation of CCR5 by n-Nonanoyl-CC chemokine ligand 14 and inhibition of allergic airway inflammation. J. Leukoc. Biol. 83: 765-773 [Abstract] [Full Text]  
• Signoret, N., Hewlett, L., Wavre, S., Pelchen-Matthews, A., Oppermann, M., Marsh, M. (2005). Agonist-induced Endocytosis of CC Chemokine Receptor 5 Is Clathrin Dependent. Mol. Biol. Cell 16: 902-917 [Abstract] [Full Text]  
• Hartley, O., Gaertner, H., Wilken, J., Thompson, D., Fish, R., Ramos, A., Pastore, C., Dufour, B., Cerini, F., Melotti, A., Heveker, N., Picard, L., Alizon, M., Mosier, D., Kent, S., Offord, R. (2004). Medicinal chemistry applied to a synthetic protein: Development of highly potent HIV entry inhibitors. Proc. Natl. Acad. Sci. USA 101: 16460-16465 [Abstract] [Full Text]  
• Lederman, M. M., Veazey, R. S., Offord, R., Mosier, D. E., Dufour, J., Mefford, M., Piatak, M. Jr., Lifson, J. D., Salkowitz, J. R., Rodriguez, B., Blauvelt, A., Hartley, O. (2004). Prevention of Vaginal SHIV Transmission in Rhesus Macaques Through Inhibition of CCR5. Science 306: 485-487 [Abstract] [Full Text]  
• Forssmann, U., Hartung, I., Balder, R., Fuchs, B., Escher, S. E., Spodsberg, N., Dulkys, Y., Walden, M., Heitland, A., Braun, A., Forssmann, W.-G., Elsner, J. (2004). n-Nonanoyl-CC Chemokine Ligand 14, a Potent CC Chemokine Ligand 14 Analogue That Prevents the Recruitment of Eosinophils in Allergic Airway Inflammation. J. Immunol. 173: 3456-3466 [Abstract] [Full Text]  
• Kawamura, T., Bruce, S. E., Abraha, A., Sugaya, M., Hartley, O., Offord, R. E., Arts, E. J., Zimmerman, P. A., Blauvelt, A. (2004). PSC-RANTES Blocks R5 Human Immunodeficiency Virus Infection of Langerhans Cells Isolated from Individuals with a Variety of CCR5 Diplotypes. J. Virol. 78: 7602-7609 [Abstract] [Full Text]  
• Veazey, R. S., Klasse, P. J., Ketas, T. J., Reeves, J. D., Piatak, M. Jr., Kunstman, K., Kuhmann, S. E., Marx, P. A., Lifson, J. D., Dufour, J., Mefford, M., Pandrea, I., Wolinsky, S. M., Doms, R. W., DeMartino, J. A., Siciliano, S. J., Lyons, K., Springer, M. S., Moore, J. P. (2003). Use of a Small Molecule CCR5 Inhibitor in Macaques to Treat Simian Immunodeficiency Virus Infection or Prevent Simian-Human Immunodeficiency Virus Infection. J. Exp. Med. 198: 1551-1562 [Abstract] [Full Text]  
• Hartley, O., Dorgham, K., Perez-Bercoff, D., Cerini, F., Heimann, A., Gaertner, H., Offord, R. E., Pancino, G., Debre, P., Gorochov, G. (2003). Human Immunodeficiency Virus Type 1 Entry Inhibitors Selected on Living Cells from a Library of Phage Chemokines. J. Virol. 77: 6637-6644 [Abstract] [Full Text]  
• Pastore, C., Picchio, G. R., Galimi, F., Fish, R., Hartley, O., Offord, R. E., Mosier, D. E. (2003). Two Mechanisms for Human Immunodeficiency Virus Type 1 Inhibition by N-Terminal Modifications of RANTES. Antimicrob. Agents Chemother. 47: 509-517 [Abstract] [Full Text]  
• Brandt, S. M., Mariani, R., Holland, A. U., Hope, T. J., Landau, N. R. (2002). Association of Chemokine-mediated Block to HIV Entry with Coreceptor Internalization. J. Biol. Chem. 277: 17291-17299 [Abstract] [Full Text]